Imetelstat: Finally a disease-modifying treatment for lower-risk myelodysplastic syndromes?
Med
; 5(3): 184-186, 2024 Mar 08.
Article
in En
| MEDLINE
| ID: mdl-38460498
ABSTRACT
Favorable results were achieved in a phase 3 clinical trial (IMerge) with the telomerase inhibitor imetelstat in transfusion-dependent patients with lower-risk myelodysplastic syndromes (MDSs) who relapsed or were refractory to erythropoiesis-stimulating agents.1 Imetelstat is likely to become a useful addition to our limited therapeutic options for patients with MDS.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myelodysplastic Syndromes
Limits:
Humans
Language:
En
Journal:
Med
/
Med (New York. Online)
Year:
2024
Document type:
Article
Affiliation country:
Alemania
Country of publication:
Estados Unidos